SLC3A2 and neoplasm: IFN-γ secreted by anti-PD-L1 immunotherapy-activated CD8+T cells markedly down-regulates SLC3A2 and SLC7A11 expression in tumor cells through the JAK1-STAT1 signaling pathway (SLC3A2 and SLC7A11 are the two subunits that constitute the cystine/glutamate antiporter, known as System Xc−), resulting in reduced cysteine uptake, compromised GPX-4 function, altered mitochondrial activity, heightened lipid peroxidation, and ultimately ferroptosis induction [17, 25].